April 12, 2022
A US federal jury has found that Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan) infringes a patent owned by Seagen, awarding the US firm US$41.8 million in damages, the Japanese company said. Daiichi Sankyo is poised to challenge the verdict...read more